← Viridian Therapeutics, Inc. (VRDN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Viridian Therapeutics, Inc. (VRDN)
Pharmaceutical Preparations · market cap $2.4B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Viridian Therapeutics (VRDN) is a clinical-stage pharma focused exclusively on Thyroid Eye Disease (TED), with two Phase 3 assets: veligrotug (VRDN-001) and VRDN-003. The company received a positive PDUFA outcome on 2026-07-02, indicating regulatory approval of its lead asset, while holding $176.3M in cash against a ~4.4-month runway at current burn rates.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VRDN-001 10 mg/kg | Phase 3 | Thyroid Eye Disease |
| Intervention/Treatment | Phase 3 | Thyroid Eye Disease |
| VRDN-001 Phase 3 Cohort (THRIVE) | Phase 3 | Thyroid Eye Disease |
| Veligrotug (VRDN-001) | Phase 3 | Thyroid Eye Disease |
| VRDN-003 | Phase 3 | Thyroid Eye Disease |
Price & technical context
3-month
-2.1%
6-month
-0.8%
12-month
-12.0%
52-wk range
$13.30–$33.78
vs 50-day MA
-13.5%
vs 200-day MA
-17.1%
Realized vol
74.0%
Max drawdown
-60.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VRDN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.